SCHEMBL5657060

SCHEMBL5657060

COc1ccccc1NC(=O)OCCN1CCN(c2ccccc2Cl)CC1

nearest known ligand 0.70

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 2/20 0.60
HTR4 Q13639 2/20 0.60
ADRA1D P25100 1/20 0.56
ADRA1A P35348 1/20 0.56
ADRA1B P35368 1/20 0.56
NPSR1 Q6W5P4 3/20 0.56
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
CYP1A2 P05177 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
CACNA1G O43497 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
MAPT P10636 1/20 0.53
TSHR P16473 1/20 0.53
RBP4 P02753 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5654727 0.94 ADRA1D (0.62) ADORA2BHTR4ADRA1DADRA1AADRA1B
SCHEMBL5656389 0.92 ADRA1D (0.65) ADRA1DADRA1AADRA1BNPSR1MEN1
SCHEMBL5654298 0.89 ADORA2B (0.51) ADORA2BHTR4ADRA1DADRA1AADRA1B
SCHEMBL5654282 0.89 KMT2A (0.59) ADRA1DADRA1AADRA1BNPSR1MEN1
SCHEMBL5654961 0.88 NPSR1 (0.72) ADORA2BHTR4ADRA1DADRA1AADRA1B
SCHEMBL5657928 0.86 MAPT (0.72) ADORA2BHTR4NPSR1MEN1KMT2A
SCHEMBL5655841 0.86 ADRA1A (0.71) ADRA1DADRA1AADRA1B
SCHEMBL5655862 0.85 NPSR1 (0.59) HTR4NPSR1MEN1KMT2AL3MBTL1
SCHEMBL5656677 0.85 ADRA1D (0.60) ADRA1DADRA1AADRA1BKMT2AMAPT
SCHEMBL5656354 0.84 DRD2 (0.53) ADRA1DADRA1AADRA1BNPSR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238693-B2 Aryl carbamate derivatives, preparation and use thereof CEREP (FR) 2007-07-03 US disclosed
US-7238693-B2 Aryl carbamate derivatives, preparation and use thereof CEREP (FR) 2007-07-03 US disclosed
US-7238693-B2 Aryl carbamate derivatives, preparation and use thereof CEREP (FR) 2007-07-03 US disclosed
US-20040058933-A1 Aryl carbamate derivatives, preperation and use thereof CEREP (FR) 2004-03-25 US disclosed
EP-1362041-A1 ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF Cerep (FR) 2003-11-19 EP disclosed
WO-2002068399-A1 ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF CEREP (FR) 2002-09-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058933-A1 Aryl carbamate derivatives, preperation and use thereof HTR4, HTR5A, HTR3C ADORA2B 72/4885HTR4 1/4885ADRA1D 265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.